Massachusetts S778 seeks to lower prescription drug costs by studying a state-run manufacturing program.
Massachusetts S778 directs the health policy commission to study the feasibility of a state-run program to manufacture generic or biosimilar drugs. The study will analyze factors contributing to drug costs, the impact on healthcare spending, and the potential benefits of such a program. The commission must submit a report with findings and recommendations within a year. The bill aims to reduce prescription drug costs and improve access to affordable drugs.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.